The University of Nevada, Reno School of Medicine

Clear Skin, Clarity in Care: Emerging IL-23 Data Highlights for Psoriasis 

MD, FAAD

MD, PhD

Evaluate severity of psoriatic disease to identify patients who meet International Psoriasis Council (IPC) eligibility criteria for systemic therapies 

Describe the emerging long-term clinical evidence for interleukin (IL)-23 inhibitors in psoriasis management 

Select the optimal therapy for patients with psoriasis who are eligible for systemic therapy

small_1 (3).jpg

thumbnail_1 (3).jpg

1 (3).jpg

Psoriasis

Live Evaluations

FC25: Clear Skin, Clarity in Care: Emerging IL-23 Data Highlights for Psoriasis 

Acne

IL Inhibitors

FC25: Clear Skin, Clarity in Care: Emerging IL-23 Data Highlights for Psoriasis

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures